Bard Port Catheter lawsuit update

Verified snapshot

The facts that anchor this dossier

Implanted ports make repeated treatment possible without repeated peripheral needle access. MDL 3081 concerns allegations that certain Bard catheter materials can degrade, fracture, migrate, or contribute to infection, and the docket is now in active bellwether proceedings.

Federal proceeding

MDL 3081

District of Arizona before Senior Judge David G. Campbell.

Actions pending

3,734

JPML inventory as of August 3, 2026, against 3,980 historical actions.

Centralized

August 8, 2023

The JPML transferred an initial ten actions and noted 38 potential tag-alongs.

Core allegations

Fracture, migration, infection, thrombosis

Allegations are contested and are not findings about every Bard port.

Bellwether posture

First trial preparations underway in 2026

A March 2026 order addressed final-pretrial work for the Cook bellwether and later cases.

Documented chronology

How the litigation reached this point

Why an implanted port is used

A totally implantable venous access port has a reservoir placed under the skin and a catheter that reaches a central vein. It can spare a patient from repeated peripheral IV placement during chemotherapy, infusions, blood draws, apheresis, or other long-term therapy. Some Bard PowerPort systems are also cleared for power injection of contrast when the correct access needle, pressure, and flow conditions are used.

The port and the catheter are different parts of one system. The reservoir is accessed through the skin, and the catheter carries fluid into the circulation. A problem can arise at the connection, along the catheter, at the tip, or in the surrounding vein. Port dysfunction can reflect a mechanical issue, a clot, malposition, or an access problem, which makes a chart notation such as 'won't flush' a starting clue rather than a diagnosis.

FDA clearance addresses substantial equivalence at the time of review, and a recall covers a defined model or manufacturing issue. Connecting a patient record to that regulatory history requires the exact model, reference number, catheter material, implant date, and lot information where available. Anything less is inference.

What plaintiffs allege and defendants contest

The JPML's August 2023 order says the centralized actions share allegations that the catheter component contains a concentration of barium sulfate that reduces material integrity and can lead to infection, fracture, migration, and thrombosis. It also identified common questions about design, testing, monitoring, adverse-event reporting, and warnings. The order reports the allegations so it can decide whether cases share facts; it does not adopt them as true.

Port-catheter fracture and migration are recognized medical events well beyond this litigation. A published series of 73 fractures across several brands found that most occurred near the port-catheter connection, with difficulty injecting as a common presentation, and case reports describe fragments migrating into the heart or pulmonary artery. That literature establishes the event as medically real and worth evaluating. The MDL's product-specific material theory is a further claim, and each individual fracture has its own cause.

FDA's MAUDE database also contains Bard reports describing fracture and migration. MAUDE is a signal-detection system. Manufacturers, clinicians, patients, and lawyers can all submit reports, and FDA cautions that the database establishes neither incidence nor causation. It identifies reported event types, which is a different thing from the chance that a port will fail.

Where the bellwether program stands

MDL 3081 moved from centralization to a structured bellwether program. In May 2025, the Arizona court selected six cases, Miller, Cook, Hicks, Divelbliss, Lattanzio, and Sorensen, plus James as an alternate. A later order set the anticipated trial sequence. The pool spans different asserted event types, so the process can test recurring evidence rather than treat one event as representative of the whole docket.

By March 2026, CMO 46 was addressing exhibit sealing, deposition designations, motions in limine, and courtroom access for the Cook trial. It also noted that Miller was one of only two thrombus cases in the pool and that Divelbliss was a fracture case. Pretrial detail at that level marks active litigation, at a stage where liability and damages remain open.

The current JPML report lists 3,734 pending actions out of 3,980 historical actions. A bellwether verdict, when it arrives, will resolve the selected case under its own evidence and governing law. It will inform the parties about recurring proof, and it will set no automatic value for thousands of other cases.

Building a reliable device chronology

The operative report, implant card, explant report, and hospital supply record can identify the port and catheter. Imaging may show tip position, fracture, migration, thrombosis, extravasation, or a retained fragment. Interventional-radiology notes explain what clinicians observed during removal or retrieval. Culture results and infectious-disease records matter when infection is alleged. Oncology records can explain why the port was still needed and whether therapy could continue through another route.

Symptoms and timelines vary widely. Difficulty flushing or drawing blood, pain near the port, fever, and arm or neck swelling all deserve medical evaluation, and chest pain or shortness of breath can be urgent. A catheter, a blood clot, an infection, and the cancer treatment itself can each produce overlapping symptoms, and only the clinical record separates them.

For litigation tracking, use the District of Arizona's case-of-interest repository and the signed PDF orders rather than a trial date copied onto a marketing page. Personal legal questions need product proof and state-specific timing rules reviewed together. An implanted Bard port and a reported complication are two facts. Eligibility is a legal conclusion that requires more.

Reader questions

Frequently asked questions